Suppr超能文献

连续心脏 MRI 定量分析蒽环类药物诱导的亚临床心肌损伤的动态变化。

Serial Cardiac MRI for Quantification of the Dynamics of Anthracycline-Induced Subclinical Myocardial Injury.

机构信息

Department of Radiology, The First Hospital of China Medical University, Shenyang, China.

Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.

出版信息

J Magn Reson Imaging. 2023 Nov;58(5):1533-1541. doi: 10.1002/jmri.28667. Epub 2023 Mar 13.

Abstract

BACKGROUND

Anthracyclines are known to be associated with chemotherapy-induced cardiotoxicity. Limited data focus on dynamic myocardial injury during the course of chemotherapy in patients with breast cancer.

PURPOSE

To investigate the variation of tissue characterization and myocardial deformation derived by cardiac MRI during anthracycline chemotherapy.

STUDY TYPE

Prospective.

POPULATION

Fifty-eight female breast cancer patients (mean age: 52.82 ± 2.61 years) were enrolled.

FIELD STRENGTH/SEQUENCE: A 3.0-T, cardiac MRI including cine balanced steady-state free precession, a modified Looker-Locker inversion recovery (MOLLI), and a fast spin echo (FSE) T2-weighted sequences were performed.

ASSESSMENT

Cardiac MRI was performed baseline and after two, four, and six cycles of chemotherapy. Assessment of global longitudinal strain (GLS), global circumstance strain (GCS), global radial strain (GRS), and strain rate (GLS-s, GCS-s, GRS-s) and T1, T2 and T2* were accomplished by CVI42. The anthracycline dose and risk factors were also collected before each cardiac MRI.

STATISTICAL TESTS

Analysis of variance (ANOVA) for repeated measures was used to compare the changes in LVEF cardiac function, strain and T1/T2/T2* parameters over time. Pearson correlation analyses were performed to estimate the potential associations between differences in myocardial characteristics (∆) and the chemotherapy cycle. A P value <0.05 was considered statistically significant.

RESULTS

LVEF was not significantly different from pretreatment MRI regarding each cycle of chemotherapy (P = 0.54). Compared with baseline, patients had significantly lower GLS (-15.85% ± 0.83%, -14.50% ± 0.88%, -12.34% ± 1.01% vs. -18.82% ± 0.92%) and GLS-s (-0.71% ± 0.07%, -0.65% ± 0.05%, -0.64% ± 0.04% vs. -0.95 ± 0.06%) and increased T2 values (57.21 ± 4.27 msec, 58.60 ± 3.93 msec, 58.10 ± 3.17 msec vs. 43.88 ± 3.28 msec) at two, four and six cycles of chemotherapy treatment. ∆GLS and ∆GLS-s were significantly associated with the chemotherapy cycle (correlation coefficients for GLS = 0.75, GLS-s = 0.75).

DATA CONCLUSION

Cardiac MRI can precisely detect the dynamic changes of anthracycline-induced subclinical myocardial injury that is represented as a gradually decrease in GLS and GLS-s. These parameters may provide new insight for monitoring risk and therapy in patients with breast cancer.

EVIDENCE LEVEL

TECHNICAL EFFICACY

Stage 1.

摘要

背景

蒽环类药物已知与化疗引起的心脏毒性有关。有限的数据集中在乳腺癌患者化疗过程中的动态心肌损伤。

目的

研究心脏 MRI 在蒽环类化疗过程中对心肌组织特征和心肌变形的变化。

研究类型

前瞻性。

人群

58 名女性乳腺癌患者(平均年龄:52.82 ± 2.61 岁)入选。

磁场强度/序列:3.0-T,心脏 MRI 包括电影平衡稳态自由进动、改良 Looker-Locker 反转恢复(MOLLI)和快速自旋回波(FSE)T2 加权序列。

评估

在化疗的两个、四个和六个周期后进行心脏 MRI。通过 CVI42 评估整体纵向应变(GLS)、整体周向应变(GCS)、整体径向应变(GRS)和应变率(GLS-s、GCS-s、GRS-s)以及 T1、T2 和 T2*。在每次心脏 MRI 之前还收集了蒽环类药物剂量和危险因素。

统计学检验

采用重复测量方差分析(ANOVA)比较 LVEF 心功能、应变和 T1/T2/T2*参数随时间的变化。Pearson 相关分析用于估计心肌特征差异(∆)与化疗周期之间的潜在关联。P 值<0.05 被认为具有统计学意义。

结果

与每次化疗前 MRI 相比,LVEF 无显著差异(P=0.54)。与基线相比,患者的 GLS(-15.85%±0.83%、-14.50%±0.88%、-12.34%±1.01%与-18.82%±0.92%)和 GLS-s(-0.71%±0.07%、-0.65%±0.05%、-0.64%±0.04%与-0.95%±0.06%)明显降低,T2 值升高(57.21±4.27 msec、58.60±3.93 msec、58.10±3.17 msec 与 43.88±3.28 msec),在两个、四个和六个化疗周期中。∆GLS 和 ∆GLS-s 与化疗周期显著相关(GLS 相关系数为 0.75,GLS-s 相关系数为 0.75)。

数据结论

心脏 MRI 可以精确检测蒽环类药物引起的亚临床心肌损伤的动态变化,表现为 GLS 和 GLS-s 逐渐降低。这些参数可能为监测乳腺癌患者的风险和治疗提供新的见解。

证据水平

2 级。

技术效果

1 级。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验